Resmetirom
Non-alcoholic steatohepatitis (MASH/NASH) with hepatic fibrosis
- CAS No.
- 920509-32-6
- Indication Class
- Gastroenterology / Hepatology
- Patent Expiry
- To be assessed
- Therapeutic Area
- Metabolism / Hepatology
- Target / Mechanism
- THRB
- Labeled Purity
- 99%+
- Registration Readiness
- GMP/DMF
- Commercialization Tier
- API (Commercialized)
- Linked Intermediates
- 7 key intermediates available
Key Intermediates for This API
Order: listed intermediates that accept enquiries first; fragments shared across several APIs rank higher| Intermediate | CAS | Shared | Action |
|---|---|---|---|
| 3,5-dichloro-4-((6-chloro-5-isopropylpyridazin-3-yl)oxy)aniline(WXG00196) | 920509-27-9 | — | |
| 3,6-dichloro-4-isopropylpyridazine | 107228-51-3 | — | |
| 3,6-Dichloropyridazine | 141-30-0 | — | |
| 4-(Propan-2-yl)pyridazine-3,6-diol | 1903632-97-2 | — | |
| 4-Amino-2,6-dichlorophenol | 5930-28-9 | — | |
| 6-(4-amino-2,6-dichlorophenoxy)-4-isopropylpyridazin-3(2H)-one | 920509-28-0 | — | |
| N-CYANOACETYLURETHANE | 6629-04-5 | — |
Listing Logic · Why It's Worth Listing
The world's first approved MASH therapy, opening a vast untreated blue-ocean; numerous follow-on pipelines will scale API demand alongside the entire class.
Metabolism / Hepatology · Marketed; available for immediate sourcing
GMP/DMF-ready; supports regulatory filing and audit in target markets
7 key intermediates available; scale-up and cost control manageable
Product Description
Resmetirom is a prescription medication that represents a significant breakthrough in the treatment of liver disease. It is the first-ever FDA-approved therapy specifically designed to treat liver fibrosis due to noncirrhotic non-alcoholic steatohepatitis (NASH).
Supply source: Unibest · Resmetirom, sourced, vetted and delivered by Unibest. Therapeutic area, indication and listing rationale are qualitative summaries based on public drug knowledge for business reference; actual registration availability and quality specifications are subject to DMF/GMP documentation and the technical agreement confirmed at order.